Clinical Trials Logo
  1. Home
  2. Non-Hodgkin Lymphoma (NHL)
  3. NCT01707628

Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab — Rituxivac  

Non-Hodgkin Lymphoma (NHL) Clinical Trial

Official title:
Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab

Clinical Trial Summary

The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma. Secondly to study the immune-response to vaccination with influenza virus vaccine, after treatment with rituximab in relation to the reconstitution of immune-function.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01707628
Study type Interventional
Source St. Antonius Hospital
Contact
Status Completed
Phase N/A
Start date October 2012
Completion date June 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Active, not recruiting NCT04702425 - VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Phase 1
Terminated NCT01050764 - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Phase 1/Phase 2
Recruiting NCT02790515 - Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Phase 2
Enrolling by invitation NCT02875548 - A Study to Assess the Long-term Safety of Tazemetostat Phase 1/Phase 2
Terminated NCT01220297 - Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Phase 2
Completed NCT04537715 - Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer Phase 1